There's a difference between relentless bashing an
Post# of 148294
Woodcock may be on the way out, but she still has power within the FDA and if they are, as NP says, already mad about constantly getting letters about Leronlimab, how does a disjointed and poorly written letter help us?
As I said, I bought more yesterday and today.
It is possible to be long this stock and not endorse every single thing someone says about it just because the thrust of their argument is positive.